PT - JOURNAL ARTICLE AU - Deng, Hai-Wei AU - Li, Jie AU - Mei, Wei-Yi AU - Lin, Xiao-Xiong AU - Xu, Qing AU - Zhai, Yuan-Sheng AU - Zheng, Qian AU - Chen, Jin-Sheng AU - Huang, Zhi-Bin AU - Cheng, Yun-Jiu TI - Incidence of Arterial and Venous Thromboembolism in Cancer Patients AID - 10.1101/2023.05.17.23290143 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.17.23290143 4099 - http://medrxiv.org/content/early/2023/05/19/2023.05.17.23290143.short 4100 - http://medrxiv.org/content/early/2023/05/19/2023.05.17.23290143.full AB - Background and Aims The reported incidence of arterial thromboembolism (ATE) and venous thromboembolism (VTE) after cancer varies. A meta-analysis was performed to define the incidence of thromboembolism (TE) in cancer patients.Methods Articles were searched in PubMed and Embase from inception to November 1, 2022. Studies reporting the incidence data or data from which incidence could be estimated among patients with cancer and the explicit follow-up duration were included.Results Seventy-four studies involving 5059134 cancer patients were identified. The incidence rate per 1000 person-years was 11.60 (95% CI 7.62-15.58) for ATE, 6.11 (95% CI 3.70-8.53) for myocardial infarction, 9.07 (95% CI 7.48-10.66) for ischemic stroke, 2.11 (95% CI 0.89-3.31) for another ATE, 26.32 (95% CI 24.46-28.18) for VTE, 12.69 (95% CI 11.51-13.87) for deep vein thrombosis, 5.94 (95% CI 5.29-6.59) for pulmonary embolism, and 13.18 (95% CI 9.93-16.42) for another VTE. In addition, the highest incidence of ATE was observed in patients with gastrointestinal cancer, while patients with pancreatic cancer had the highest incidence of VTE. The risk of ATE and VTE increased at the initial stage of cancer, and then declined and became non-significant.Conclusion This meta-analysis provided overall estimates of ATE and VTE incidence in cancer patients, adding an important insight into the trajectory of the development of TE in cancer patients, which could help reduce the risk of TE in cancer patients in the future.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe data that support the findings of this study are available from the corresponding author, upon reasonable request.ATEArterial ThromboembolismMIMyocardial InfarctionISIschemic StrokeVTEVenous ThromboembolismDVTDeep Vein ThrombosisPEPulmonary EmbolismCIconfidence interval